BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29378238)

  • 1. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
    Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M
    Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
    Reich TR; Schwarzenbach C; Vilar JB; Unger S; Mühlhäusler F; Nikolova T; Poplawski A; Baymaz HI; Beli P; Christmann M; Tomicic MT
    Cell Mol Life Sci; 2021 Jul; 78(14):5587-5604. PubMed ID: 34100981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
    Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
    Bao Z; Chen L; Guo S
    J Cell Biochem; 2019 Jun; 120(6):10205-10214. PubMed ID: 30592329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis.
    Li XX; Xu JK; Su WJ; Wu HL; Zhao K; Zhang CM; Chen XK; Yang LX
    Kaohsiung J Med Sci; 2024 Feb; 40(2):161-174. PubMed ID: 37873881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
    He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
    Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
    Lang F; Cornwell JA; Kaur K; Elmogazy O; Zhang W; Zhang M; Song H; Sun Z; Wu X; Aladjem MI; Aregger M; Cappell SD; Yang C
    Neuro Oncol; 2024 Jun; 26(6):1083-1096. PubMed ID: 38134889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
    Qin T; Mullan B; Ravindran R; Messinger D; Siada R; Cummings JR; Harris M; Muruganand A; Pyaram K; Miklja Z; Reiber M; Garcia T; Tran D; Danussi C; Brosnan-Cashman J; Pratt D; Zhao X; Rehemtulla A; Sartor MA; Venneti S; Meeker AK; Huse JT; Morgan MA; Lowenstein PR; Castro MG; Yadav VN; Koschmann C
    Cell Rep; 2022 Jan; 38(2):110216. PubMed ID: 35021084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stalled replication forks within heterochromatin require ATRX for protection.
    Huh MS; Ivanochko D; Hashem LE; Curtin M; Delorme M; Goodall E; Yan K; Picketts DJ
    Cell Death Dis; 2016 May; 7(5):e2220. PubMed ID: 27171262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
    George SL; Lorenzi F; King D; Hartlieb S; Campbell J; Pemberton H; Toprak UH; Barker K; Tall J; da Costa BM; van den Boogaard ML; Dolman MEM; Molenaar JJ; Bryant HE; Westermann F; Lord CJ; Chesler L
    EBioMedicine; 2020 Sep; 59():102971. PubMed ID: 32846370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
    Agnihotri S; Burrell K; Buczkowicz P; Remke M; Golbourn B; Chornenkyy Y; Gajadhar A; Fernandez NA; Clarke ID; Barszczyk MS; Pajovic S; Ternamian C; Head R; Sabha N; Sobol RW; Taylor MD; Rutka JT; Jones C; Dirks PB; Zadeh G; Hawkins C
    Cancer Discov; 2014 Oct; 4(10):1198-213. PubMed ID: 25100205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.